4//SEC Filing
WENTWORTH KORY JAMES 4
Accession 0001689375-24-000065
CIK 0001689375other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 4:47 PM ET
Size
9.1 KB
Accession
0001689375-24-000065
Insider Transaction Report
Form 4
WENTWORTH KORY JAMES
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-11-11$19.98/sh−8,637$172,562→ 73,849 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-11−6,000→ 37,157 totalExercise: $2.10Exp: 2030-11-10→ Common Stock (6,000 underlying) - Exercise/Conversion
Common Stock
2024-11-11$2.10/sh+6,000$12,600→ 82,486 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Entrada Therapeutics, Inc.
CIK 0001689375
Entity typeother
Related Parties
1- filerCIK 0001725663
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 4:47 PM ET
- Size
- 9.1 KB